147 related articles for article (PubMed ID: 37851898)
41. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
42. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
[TBL] [Abstract][Full Text] [Related]
43. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
[TBL] [Abstract][Full Text] [Related]
44. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
45. Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China.
Sun JJ; Liu L; Wang JR; Shen YZ; Qi TK; Wang ZY; Tang Y; Song W; Chen J; Zhang RF
Chin Med J (Engl); 2020 Dec; 133(23):2796-2802. PubMed ID: 33273327
[TBL] [Abstract][Full Text] [Related]
46. The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
Choi JH; Lim I; Byun BH; Kim BI; Choi CW; Kang HJ; Shin DY; Lim SM
PLoS One; 2022; 17(9):e0273839. PubMed ID: 36156599
[TBL] [Abstract][Full Text] [Related]
47. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
[TBL] [Abstract][Full Text] [Related]
48. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
49. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
[No Abstract] [Full Text] [Related]
50. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
51. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.
Camus V; Belot A; Oberic L; Sibon D; Ghesquières H; Thieblemont C; Fruchart C; Casasnovas O; Michot JM; Molina TJ; Bosly A; Joubert C; Haioun C; Nicolas-Virelizier E; Feugier P; Fitoussi O; Delarue R; Tilly H
Blood Adv; 2022 Dec; 6(24):6169-6179. PubMed ID: 35737565
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
54. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
56. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Meeuwes FO; Brink M; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer L; Woei-A-Jin S; Visser O; Oostvogels R; Jansen PM; Diepstra A; Snijders TJF; Plattel WJ; Huls GA; Vermaat JSP; Nijland M
Eur J Cancer; 2022 Nov; 176():100-109. PubMed ID: 36208568
[TBL] [Abstract][Full Text] [Related]
57. The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.
Liu Y; Gu JJ; Yang L; Tsai PC; Guo Y; Xue K; Xia Z; Liu X; Lv F; Cao J; Hong X; Mavis C; Hernandez-Ilizaliturri FJ; Zhang Q
Aging (Albany NY); 2020 Dec; 13(1):181-193. PubMed ID: 33288735
[TBL] [Abstract][Full Text] [Related]
58. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
59. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
60. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
Vähämurto P; Mannisto S; Pollari M; Karjalainen-Lindsberg ML; Mäkitie AA; Leppä S
Eur J Haematol; 2019 Jun; 102(6):457-464. PubMed ID: 30834564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]